To estimate the incidence, prevalence, frequency, and duration of incarceration and to identify risk factors for incarceration among women at risk for human immunodeficiency virus (HIV) in the United States.
Methods:
During semiannual study visits in a multicenter cohort study, 970 HIV sero-negative participants at risk for HIV were asked about their own incarceration (10/2007–09/2017) and incarceration of sexual partners (10/2013–09/2017). We used descriptive statistics and multivariable log-binomial regression to identify baseline predictors of incident incarceration.
Results:
Median follow-up time across the 970 participants was 5.5 years (IQR 3.5–9.5). Nearly half (n = 453, 46.7%) of participants were incarcerated during or before the study, and the incarceration rate was 5.5 per 100 person-years. In multivariable models, incident incarceration was associated with prior incarceration (RR 5.20, 95% CI: 3.23–8.41) and noninjection drug use (RR 1.57, 95% CI: 1.10–2.25).
Conclusions:
Incarceration is common for women at risk for HIV. Prevention interventions that address the complex interplay of drug use, sex exchange, and housing instability for women who have experienced incarceration have the potential to reach an important group of U.S. women at risk of HIV infection.
Get full access to this article
View all access options for this article.
References
1.
KhanMR, MillerWC, SchoenbachVJ, et al.Timing and duration of incarceration and high-risk sexual partnerships among African Americans in North Carolina. Ann Epidemiol, 2008; 18:403–410.
2.
BaetenJM, DonnellD, NdaseP, et al.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med, 2012; 367:399–410.
3.
WidmanL, NoarSM, GolinCE, WilloughbyJF, CrosbyR. Incarceration and unstable housing interact to predict sexual risk behaviours among African American STD clinic patients. Int J STD AIDS, 2014; 25:348–354.
4.
WiseA, FinlaysonT, NerlanderL, SioneanC, Paz-Bailey G; for the NHBS StudyGroup. Incarceration, sexual risk-related behaviors, and HIV infection among women at increased risk of HIV infection, 20 United States cities. J Acquir Immune Defic Syndr, 2017; 75(S3):S261–S267.
5.
EppersonMW, KhanMR, MillerDP, PerronBE, El-BasselN, GilbertL. Assessing criminal justice involvement as an indicator of human immunodeficiency virus risk among women in methadone treatment. J Subst Abuse Treat, 2010; 38:375–383.
6.
KhanMR, EppersonMW, Mateu-GelabertP, BolyardM, SandovalM, FriedmanSR. Incarceration, sex with an STI- or HIV-infected partner, and infection with an STI or HIV in Bushwick, Brooklyn, NY: A social network perspective. Am J Public Health, 2011; 101:1110–1117.
7.
RogersSM, KhanMR, TanS, TurnerCF, MillerWC, ErbeldingE. Incarceration, high-risk sexual partnerships and sexually transmitted infections in an urban population. Sex Transm Infect, 2012; 88:63–68.
8.
KnittelAK, LambdinBH, ComfortML, KralAH, LorvickJ. Sexual risk and criminal justice involvement among women who use drugs. AIDS Behav, 2019; 23:3366–3374.
9.
JamesDJ, GlazeLE. Mental Health Problems of Prison and Jail Inmates. Washington, DC: Bureau of Justice Statistics, BJS Bull 2006 (NCJ 213600).
10.
CarsonEA. Prisoners in 2016. Washington DC: Bureau of Justice Statistics, BJS Bull. 2018 (NCJ 251149).
11.
AdimoraAA, SchoenbachVJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis, 2005; 191(S):S115–S122.
12.
BrownMM, Chesney-LindM. Women's Incarceration in the United States. In: GriffinOH, III, WoodwardVH, eds. Routledge Handbook of Corrections in the United States. New York, NY: Routledge, 2017.
13.
ZibbellJE, AsherAK, PatelRC, et al.Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health, 2018; 108:175–181.
14.
StatonM, CiciurkaiteG, OserC, et al.Drug use and incarceration among rural Appalachian women: Findings from a jail sample. Subst Use Misuse, 2018; 53:931–941.
15.
ACOG Committee on Gynecologic Practice. Committee Opinion 595: Preexposure prophylaxis for the prevention of human immunideficiency virus. Obstet Gynecol, 2014; 123:1133–1136.
16.
RutledgeR, MaddenL, OgbuaguO, MeyerJP. HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care, 2018; 30:1282–1289.
17.
Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: A clinical practice guideline. Available at: www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March, 2018. Accessed March, 2020.
18.
SmithDK, VanH and elM, GreyJ. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol, 2018; 28:850–857 e859.
19.
StatonM, CiciurkaiteG, HavensJ, et al.Correlates of injection drug use among rural Appalachian women. J Rural Health, 2018; 34:31–41.
20.
AuerbachJD, KinskyS, BrownG, CharlesV. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDs, 2015; 29:102–110.
21.
PatelAS, GoparajuL, SalesJM, et al.PrEP eligibility among at-risk women in the Southern United States: Associated factors, awareness, and acceptability. J Acquir Immune Defic Syndr, 2019; 80:527.
22.
AdimoraAA, ColeSR, EronJJ. US Black women and human immunodeficiency virus prevention: Time for new approaches to clinical trials. Clin Infect Dis, 2018; 65:324–327.
23.
SeidmanD, WeberS. Integrating preexposure prophylaxis for human immunodeficiency virus prevention into women's health care in the United States. Obstet Gynecol, 2016; 128:37–43.
24.
Brinkley-RubinsteinL, DauriaE, Tolou-ShamsM, et al.The path to implementation of HIV pre-exposure prophylaxis for people involved in criminal justice systems. Curr HIV/AIDS Rep, 2018; 15:93–95.
25.
KnittelAK.Resolving health disparities for women involved in the criminal justice system. N C Med J, 2019; 80:363–366.
26.
AdimoraAA, RamirezC, BenningL, et al.Cohort Profile: The Women's Interagency HIV Study (WIHS). Int J Epidemiol, 2018; 47:393–394i.
27.
RubinDC, BaddeleyAD. Telescoping is not time compression: A model. M&C, 1989; 17:653–661.
MeurerWJ, TollesJ. Logistic regression diagnostics: Understanding how well a model predicts outcomes. JAMA, 2017; 317:1068–1069.
30.
HankelJ, HeilM, DeweyS, MartinezN. Characteristics of women seeking services at a transitional housing facility for women leaving street-based sex work: Implications for social service providers. J Soc Serv Res, 2015; 42:41–56.
31.
LorvickJ, ComfortM, KralAH, LambdinBH. Exploring lifetime accumulation of criminal justice involvement and associated health and social outcomes in a community-based sample of women who use drugs. J Urban Health, 2017; 95:584–593.
32.
KnittelAK, LopezWD, GrahamLF, SnowRC. Criminal justice involvement among young people exchanging sex in detroit. Child Youth Serv Rev, 2018; 93:1–11.
33.
WesternB, PetitB. Incarceration & social inequality. Daedalus, 2010; 139:8–19.
34.
KajsturaA. Women's Mass Incarceration: The Whole Pie 2018. Prison Policy Initiative. Available at: www.prisonpolicy.org/reports/pie2018women.html. Published November, 2018. Accessed August, 2019.
35.
LeverentzA.Churning through the system: How people engage with the criminal justice system when faced with short sentences. In: After Imprisonment. Vol 77. Melbourne: Emerald Publishing Limited, 2018:123–143.
36.
GlazeLE, KaebleD. Correctional populations in the United States,Washington, DC: Bureau of Justice Statistics, 2015.
37.
SmithVC.Substance-abusing female offenders as victims: Chronological sequencing of pathways into the criminal justice system. Vict Offender, 2017; 12:113–137.
38.
HerbstJH, Branscomb-BurgessO, GelaudeDJ, SethP, ParkerS, FogelCI. Risk profiles of women experiencing initial and repeat incarcerations: Implications for prevention programs. AIDS Educ Prev, 2016; 28:299–311.
39.
WaltersSM, RiveraAV, ReillyKH, et al.Exchange sex among persons who inject drugs in the New York metropolitan area: The importance of local context, gender and sexual identity. AIDS Behav, 2018; 22:2773–2787.
40.
FogelCI, GelaudeDJ, CarryM, et al.Context of risk for HIV and sexually transmitted infections among incarcerated women in the south: Individual, interpersonal, and societal factors. Women Health, 2014; 54:694–711.
41.
Cotten-OldenburgNU, JordanBK, MartinSL, KupperL.Women inmates' risky sex and drug behaviors: Are they related?. Am J Drug Alcohol Abuse 1999;25:129–149.
42.
BlankenshipKM, Del Rio GonzalezAM, KeeneDE, GrovesAK, RosenbergAP. Mass incarceration, race inequality, and health: Expanding concepts and assessing impacts on well-being. Soc Sci Med, 2018; 215:45–52.
43.
State Medical Marijuana Laws. National Conference of State Legislators. Available at: www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Published March, 2020. Accessed June, 2020.
44.
FirthCL, MaherJE, DilleyJA, DarnellA, LovrichNP. Did marijuana legalization in Washington State reduce racial disparities in adult marijuana arrests?. Subst Use Misuse, 2019; 54:1582–1587.
45.
ThompsonBY.“Good moral characters”: How drug felons are impacted under state marijuana legalization laws. Contemp Justice Rev, 2017; 20:211–226.
46.
KoblinBA, GrantS, FryeV, et al.HIV sexual risk and syndemics among women in three urban areas in the United States: Analysis from HVTN 906. J Urban Health, 2015; 92:572–583.
47.
SingerMC, EricksonPI, BadianeL, et al.Syndemics, sex and the city: Understanding sexually transmitted diseases in social and cultural context. Soc Sci Med, 2006; 63:2010–2021.
48.
GilbertL, RajA, HienD, StockmanJ, TerlikbayevaA, WyattG. Targeting the SAVA (substance abuse, violence, and AIDS) syndemic among women and girls: A global review of epidemiology and integrated interventions. J Acquir Immune Defic Syndr, 2015; 69:S118–S127.
49.
El-BasselN, StrathdeeSA. Women who use or inject drugs: An action agenda for women-specific, multilevel, and combination HIV prevention and research. J Acquir Immune Defic Syndr, 2015; 69:S182–S190.
50.
SpringerSA, LarneyS, Alam-MehrjerdiZ, AlticeFL, MetzgerD, ShoptawS. Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: Progress, gaps, and future directions. J Acquir Immune Defic Syndr, 2015; 69(S2):S155–S161.
51.
NunnAS, Brinkley-RubinsteinL, OldenburgCE, et al.Defining the HIV pre-exposure prophylaxis care continuum. AIDS, 2017; 31:731–734.
52.
GoparajuL, PraschanNC, Warren-JeanpiereL, ExpertonLS, YoungMA, KassayeS. Stigma, partners, providers and costs: Potential barriers to PrEP uptake among US women. J AIDS Clin Res, 2017; 8:730.
53.
SmithDK, Van HandelMM, WolitskiRJ, et al.Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep, 2015; 64:1291–1295.
54.
PettitB, WesternB. Mass Imprisonment and the Life Course: Race and Class Inequality in U.S. Incarceration. Am Sociol Rev, 2004; 69:151–169.
55.
EhrmannT.Community-based organizations and HIV prevention for incarcerated populations: Three HIV prevention program models. AIDS Educ Prev, 2002; 14(Suppl 5):75–84.
56.
BeckwithCG, ZallerND, FuJJ, MontagueBT, RichJD. Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr, 2010; 55(Suppl 1):S49–S55.
57.
LeukefeldC, HavensJ, TindallMS, et al.Risky relationships: Targeting HIV prevention for women offenders. AIDS Educ Prev, 2012; 24:339–349.
